HLA-B* 1502 for Carbamazepine Toxicity

HLA-B* locus is evaluated to identify the HLA-B 1502 variation which is linked to Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) complications in patients receiving Carbamazepine

Details

Clinical studies have demonstrated association between some HLA genotypes and drug induced adverse skin reactions. Presence of HLA B*15:02 allele increases the risk of developing Toxic Epidermal Necrolysis (TEN) or Stevens- Johnson Syndrome (SJS) which is a milder form of TEN. The frequency of this allele is 10-15% in Chinese, 2-4% in South East Asians including Indians and <1% in Japanese & Koreans. This allele has also been associated with adverse reactions to Lamotrigene used for treating Epilepsy and Bipolar disorder.

Also name as HLA B*15:02, HLA-B15

Test Code: MGM337

Technique: Next Generation Sequencing

Sample: 4 mL (3 mL min.) Peripheral blood; purified genomic DNA; buccal swabs (4) for patients on chemotherapy or anemic patients with a WBC count <1000/uL

Sample Remark: EDTA anticoagulated peripheral blood; DNA in sealed Eppendorf tube; buccal swabs in a sterile container without any additives

Temperature: 2-8°C

Reported on: 14th working day by 7:00 p.m.